Mar 11, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingVIEW RELEASE
Mar 10, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingVIEW RELEASE
Mar 05, 2026
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid WithdrawalVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Mar 13, 2026 01:46 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.51
CHANGE
-0.04 (-2.68%)